HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ZJYL
Jin Medical International Ltd.
There isn't enough reported data to score ZJYL yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ZJYL Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Weak |
ZJYL's profitability is currently healthy, but its balance sheet is weak. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ZJYL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $2.19 | -43% |
| Fair | 18x | $3.67 | -5.1% |
| Current | 21x | $3.87 | — |
| Expensive | 161x | $32.23 | +733% |
Historical ranges are pointers, not guarantees.
ZJYL's PE is 21x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ZJYL Forward outlook
There aren't enough analyst estimates for ZJYL to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ZJYL Earnings Per Share
ZJYL and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ZJYL in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ZJYL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $8.9M | -9.7% |
| Q3 2025 | $10.8M | -17% |
| Q1 2025 | $9.9M | -6.4% |
| Q3 2024 | $12.9M | +35% |
| Q1 2024 | $10.6M | +3% |
| Q3 2023 | $9.6M | -1.6% |
| Q1 2023 | $10.3M | +8.3% |
| Q3 2022 | $9.7M | -14% |
ZJYL's revenue is growing: $9M last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -7.2% | -19 points |
| Q3 2025 | 9.8% | -1.6 points |
| Q1 2025 | -4.6% | -22 points |
| Q3 2024 | 19% | +7.1 points |
| Q1 2024 | 12% | +0.9 points |
| Q3 2023 | 11% | +4.5 points |
| Q1 2023 | 17% | -2.3 points |
| Q3 2022 | 11% | -1.6 points |
ZJYL's operating margin was −7.2% last quarter, down 19 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ZJYL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.7M | -633% |
| Q3 2025 | -$4.2M | -$2.9M |
| Q1 2025 | $510.9K | +$544.6K |
| Q3 2024 | -$1.3M | -607% |
| Q1 2024 | -$33.7K | -101% |
| Q3 2023 | $260K | -84% |
| Q1 2023 | $2.7M | +$2.8M |
| Q3 2022 | $1.6M | -19% |
ZJYL's free cash flow was −$8M over the past year, against $5M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ZJYL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ZJYL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +2 shares |
| 1 year | +0.1% | +7.3K shares |
| 3 years | -61% | -12.2M shares |
ZJYL has 8M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q3 2022 | — |
| Q1 2022 | — |
| Q3 2021 | — |
| Q1 2021 | — |
| Q3 2020 | — |
| Q1 2020 | — |
| Q3 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ZJYL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 13.4x | High |
| Q1 2025 | 2.1x | Moderate |
| Q3 2024 | 0.8x | Very low |
| Q1 2024 | 0.3x | Very low |
ZJYL's net debt is about 13 years of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ZJYL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.7 | Neutral |
| Stochastic | 61.8 | Neutral |
ZJYL's weekly RSI is 66 (neutral) and its Stochastic is 62 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ZJYL PE vs Healthcare Sector
| Metric | ZJYL | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 20% below |
| PE % | 55 | 39 | 16 pts above |
ZJYL is trading at 21x earnings, a 20% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
ZJYL has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus ZJYL above 3 of 4.
ZJYL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.45 | 58% above |
| 20 week MA | $2.32 | 67% above |
| 50 week MA | $2.64 | 47% above |
| 100 week MA | $8.05 | 52% below |
ZJYL has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 52% below its 100-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
ZJYL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $7.45 | $248.1 | +3230% |
| 2024 | $248.1 | $21.0 | -92% |
| 2025 | $21.0 | $4.46 | -79% |
| 2026 YTD | $4.46 | $3.87 | -13% |
ZJYL has the edge over HIMS on returns for 2026, with the stronger performance.